ccc

GLPs offer powerful weight loss opportunity. For many, cost prevents access to treatment and some patients seek cheaper options through compounding. The Obesity Medical Association and this author recommend against use of compounded agents. There are safety considerations with compounded GLPs. Recently the FDA reported: 605 reports of adverse events associated with compounded semaglutide 545 reports of adverse events associated with compounded tirzepatide Is there a better op